December, like every December, was more hectic than normal, and I wasnt weighing myself, and I wasnt paying attention to food
The rates are remarkably similar across all three, despite their different mechanisms: Semaglutide: Nausea approximately 18%, diarrhea approximately 12%, vomiting approximately 8% Tirzepatide: Nausea 17-22% (dose dependent), diarrhea 13-16%, vomiting 6-10% Retatrutide: Nausea 16-25% (dose dependent), diarrhea 15-22%, vomiting 8-13% The pattern holds consistently
In addition to BMI, new restrictions have been introduced, such as the need to first try and must fail with non-GLP-1 weight-loss drugs, the presence of comorbidities such as uncontrolled high blood pressure (above 140/90), or mandatory participation in a weight-loss program
they can be profoundly debilitating, requiring extensive medical intervention and causing significant long-term health issues
Injectable GHK-Cu is sold online as a "research chemical." It is not FDA-approved for body contouring
By acting like GLP-1, Semaglutide sends signals to your brain that make you feel full for a longer time
